MyOme, a clinical whole genome testing and polygenic risk modeling (PRS) company, has launched its new coronary artery disease (CAD) PRS product, Integrated PRS, CAD (CAD iPRS), which combines whole-genome sequencing data with traditional clinical risk factors to offer a more accurate and ancestrally validated 10-year absolute risk assessment for CAD, a significant public health issue affecting approximately 47% of adults and causing about 375,000 deaths annually in the U.S.

This launch is supported by a validation study, presented at the American College of Medical Genetics Annual Meeting, demonstrating that CAD iPRS, by integrating a cross-ancestry polygenic risk score (caPRS) with the ASCVD Pooled Cohort Equation (PCE), significantly improves 10-year absolute risk prediction and identifies up to 27 additional CAD cases per 1,000 individuals in the borderline/intermediate PCE group, particularly benefiting diverse patient populations where current tools often fall short. CAD iPRS empowers physicians to more accurately assess risk across diverse patient populations, enabling personalized screening and treatment plans to potentially delay or prevent CAD onset, with the product now available as part of MyOme's broader suite of clinical offerings. Furthermore, MyOme has partnered with Penn Medicine on the COMPASS-CAD clinical trial, a prospective study that will assess the real-world value of CAD iPRS by providing it to 1,000 recruited participants (ages 40-70, no history of CAD, from Penn Medicine BioBank cohorts with borderline or intermediate CAD risk) to monitor clinical interventions and patient outcomes, especially for those reclassified as high-risk by CAD iPRS, ultimately aiming to support the inclusion of this more holistic risk assessment in routine clinical practice and improve patient compliance with interventions like statins and lifestyle changes to enhance outcomes.